SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 26th, 2020 • Bioxytran, Inc • Pharmaceutical preparations • Nevada
Contract Type FiledFebruary 26th, 2020 Company Industry JurisdictionThis SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February 19, 2020, by and between BIOXYTRAN, INC., a Nevada corporation, with headquarters located at 233 Needham Street, Suite 300, Newton MA, 02464 (the “Company”), and CROWN BRIDGE PARTNERS, LLC, a New York limited liability company, with its address at 1173a 2nd Avenue, Suite 126, New York, NY 10065 (the “Buyer”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 26th, 2020 • Bioxytran, Inc • Pharmaceutical preparations • New York
Contract Type FiledFebruary 26th, 2020 Company Industry JurisdictionThis SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February 18, 2020, by and between BIOXYTRAN, INC., a Nevada corporation, with its address at 233 Needham St., Ste 300, Newton, MA 02464 (the “Company”), and POWER UP LENDING GROUP LTD., a Virginia corporation, with its address at 111 Great Neck Road, Suite 216, Great Neck, NY 11021 (the “Buyer”).
COMMON STOCK PURCHASE WARRANT BIOXYTRAN, INC.Common Stock Purchase Warrant • February 26th, 2020 • Bioxytran, Inc • Pharmaceutical preparations • Nevada
Contract Type FiledFebruary 26th, 2020 Company Industry JurisdictionThis COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the funding of purchase price of $49,500.00 for the convertible promissory note in the principal amount of $55,000.00 issued by the Company (as defined below) to the Holder (as defined below) on February 19, 2020) (the “Note”)), Crown Bridge Partners, LLC (including any permitted and registered assigns, the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of issuance hereof, to purchase from Bioxytran, Inc., a Nevada corporation (the “Company”), 22,000 shares of Common Stock (as defined below) (the “Warrant Shares”) at the Exercise Price per share then in effect (whereby such number may be adjusted from time to time pursuant to the terms and conditions of this Warrant).